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Equivalence of hydrofluoroalkane
(HFA) and chlorofluorocarbons (CFC)
formulations of inhaled
beclomethasoneWe read with interest the recent article of Milanowski et al.
(1) which reported an apparent equivalent anti-asthmatic
eect of low (400 mg per day) and high (2000 mg per day)
doses of HFA-134a (Norton Healthcare Ltd, London,
U.K.) and CFC formulations of beclomethasone dipropio-
nate (BDP). In order to evaluate the relative potency of two
inhaled corticosteroid formulations, it is necessary to
compare anti-asthmatic eects on the steep part of the
dose-response curve, preferably using at least three doses
(2). In the study of Milanowski et al. baseline values for
mean forced expiratory volume in 1 sec (FEV1) showed that
both groups were well matched for the low dose study (67%
predicted) and the high dose study (70% predicted). The
primary ecacy variable from the intent-to-treat popula-
tions showed no evidence of a dose-response eect between
2000 mg per day and 400 mg per day for either the CFC or
HFA formulations, in terms of the change in FEV1 between
baseline and end-point after 6 weeks of treatment. For
HFA-BDP the mean change in FEV1 was 04 l at 400 mg
and 02 l for 2000 mg, whilst for CFC-BDP values were 03 l
and 03 l, respectively. In other words, for the patients who
were studied, 400 mg day71 of either CFC or HFA-BDP
was on the plateau part of the dose-response curve. Hence it
is not possible to make any valid conclusions regarding
therapeutic equivalence from these data.
Had the authors evaluated doses of BDP less than 400 mg
per day on the steep part of the dose-response curve, it is
conceivable that dierences in anti-asthmatic potency
between the two formulations may have become evident.
In this respect we have recently performed a pharmacoki-
netic study to compare the systematic bioequivalence of a
1000 mg nominal dose of HFA-134a BDP metered dose
inhaler (as Beclazone-CFC free 250 mg per actuation,
Norton-Waterford, Ireland) or CFC containing metered
dose inhaler (Beclazone 250 mg per actuation) (3). The
HFA-134a BDP inhaler was identical to that used in the
study of Milanowski et al. Plasma levels of beclometha-
sone-17-monopropionate (17-BMP) were measured over a
12 h period after inhalation. The results showed mean
values for the area under the curve (AUC0–12) were 15 fold
greater, and mean values for maximum plasma concentra-
tion (Cmax) were 19 fold greater when comparing HFA-
BDP vs. CFC-BDP formulations. Furthermore, the 90%
confidence interval for the ratio of HFA-BDP to CFC-BDP
was outside of that established for bioequivalence for both
AUC (90% CI 133–195) and Cmax (90% CI 157–261).0954-6111/00/020177+07 $35?00/0These pharmacokinetic data would therefore suggest that
the HFA and CFC formulations of BDP are not
bioequivalent. Indeed, this has been shown with another
HFA-134a formulation of BDP metered dose inhaler (3M
Healthcare Limited, Loughborough, U.K.) where the
relative dose ratio for potency for HFA-BDP versus
CFC-BDP was 26, as assessed by comparing eects on
the steep part of the dose-response curve FEV1 in patients
with moderate to severe asthma (4).
Caution should therefore be exercised in interpreting the
data of Milanowski et al. in terms of making recommenda-
tions for directly substituting HFA (Norton Healthcare) for
CFC formulations of BDP metered dose inhaler on a
microgram equivalent basis. Properly designed clinical
trials using a dose-response comparison are required in
order to provide more rational dosing recommendations
when switching between the two products.
B. J. LIPWORTH AND C. M. JACKSON
Department of Clinical Pharmacology,
Ninewells Hospital and Medical School,
University of Dundee DD1 9SY, Scotland U.K.
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Is inhaled beclomethasone (BDP)
with a non-CFC propellant equivalent
to the CFC propellant formulations?The reformulation of beclomethasone dipropionate (BDP)
metered dose inhalers (MDIs), using hydrofluoroalkane
(HFA) propellants to replace chlorofluorocarbons (CFC) is# 2000 HARCOURT PUBLISHERS LTD
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(QVAR-3M pharmaceuticals) and a generic version is
described in the studies of Milanowski et al. (1). Most
MDI preparations are a suspension of drug particles.
However a BDP suspension in an HFA propellant is
dicult to achieve. Some manufacturers have solved this
problem by using an solvent (ethanol), in combination with
HFA propellant, to produce a solution aerosol. Although
not yet reported in the literature the indications are that
pharmaceutically there is little dierence between QVAR
and the generic HFA MDI formulation of BDP (Norton
Healthcare Ltd, U.K.) used by Milanowski et al. (1). There
is also a lack of pharmacokinetic data to provide
indications about the systemic delivery for the generic
HFA BDP aerosol. Clinical studies comparing QVAR to
CFC BDP MDIs have shown that the dose could be halved
(2,3) but others have shown dose comparability (4,5). The
report by Milanowski et al. (1), like the previous studies (2–
5), was not designed to be able to make firm recommenda-
tions about the clinical dose.
The BDP particles emitted from solution aerosols are
much smaller than conventional MDI suspensions. It has
been quoted that the majority of the particles in the
respirable fraction of QVAR are 52mm compared with
1–6 mm for the BDP CFC MDIs (6). The eect of inhaling
such small particles may be to increase lung deposition with
potentially increased delivery to the alveoli (7). If lung
deposition of BDP to the lungs, especially the peripheral
zones, is increased and the amount swallowed is decreased
then there will be a significant increase in the systemic
availability. Pharmacokinetic studies in adults have shown
that 200 mg of BDP from an HFA MDI (QVAR) delivers
134% more to the systemic circulation than 400 mg from
the CFC MDI formulations of BDP (8). This data shows
that, in adults, if comparable doses would have have been
used the total systemic delivery of drug from the HFA BDP
aerosol would be 227 times more than a CFC MDI. A
recent study in children (aged 10–14 years) indicates that
the breath-actuated version of this BDP HFAMDI delivers
275 times more drug to the systemic circulation as a CFC
MDI attached to a large volume spacer (9).
Dosage reductions due to increased systemic availability,
from these new MDI formulations, are essential because
inhaled corticosteroids are associated with dose-related
systemic adverse eects (10). This relationship is exponen-
tial in nature with a greater eect as the dose is increased.
The dose response relationship for the clinical eect is
exactly the opposite and less pronounced. There is a
relatively flat nature to the dose-response curve for lung
function parameters within the therapeutic dosage range
for inhaled corticosteroids (11,12).
Milanowski et al. (1) have reported the results from two
parallel group studies. The ‘low’ dose parallel group study
involved steroid naı¨ve asthmatics with a baseline mean
forced expiratory volume in 1 sec (FEV1)% predicted of
about 67% for the HFA and CFC preparations. The BDP
doses were 400 mg per day and the mean increase in FEV1
was 03 and 04 l respectively. The high dose parallel group
study involved asthmatics inhaling 800–2000 mg BDP per
day prior to study entry. All received 2000 mg BDP per dayas the HFA or CFC aerosol. Baseline data were similar to
the low dose study with a mean FEV1% predicted of 70%.
The mean increase in FEV1 was 03 and 02 l respectively.
All these results may have been maximal responses at the
plateau of the dose response relationship.
The concluding statement by Milanowski et al. (1) that
patients may be switched directly from their existing CFC-
formulated BDP MD1 to the generic cannot be made. This
study (1), like many previous studies was under-powered to
provide positive evidence of equivalence using the normal
method of non-overlapping 90% confidence intervals. It is
also important to study comparative ecacy of doses on
the steep part of the dose response curve in order to make
true comparisons. The study reported by Busse et al. (5)
indicates a dose response relationship for BDP using HFA
and the CFC MDIs but the response is fairly flat due to the
large doses used. Therefore for their the outcome data they
have used a Finney’s Bioassay to show the HFA formula-
tion was 26 times more potent than the CFC version.
However the 95% confidence interval for this value was
11–111 and thus on this basis the greater potency (to show
a marginally better response in the FEV1) may not proven
with respect to clinical management.
Seamless transition is only possible if the amounts
deposited in the lungs and delivered to the systemic
circulation are the same and when the patient notices little
dierence in taste and the emitted plume. The switch to
HFA aerosols seems to have turned into a race to be first
rather than a quest to produce preparations which enable
seamless transition. This represents a threat to the manage-
ment of stable asthma patients. The generic BDP HFA
aerosol used by Milanowski et al. (1) has been licensed in
some countries as a dose for dose swap for the CFC
formulation. For QVAR the recommendation is to halve
the dose for well-controlled patients. If both were available
in a single country with dierent dosage recommendations
then problems will be created when a prescription for a
beclomethasone HFA metered dose inhaler is presented for
dispensing. In the future the availability of a new
formulation which ensures seamless transition between
CFC and HFA beclomethasone aerosols will now create
more confusion.
H. CHRYSTYN
Pharmacy Practice, The School of Pharmacy,
University of Bradford, Bradford, BD7 IDP, U.K.
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Lipworth, Dr C.M. Jackson and
Prof. H. Chrystyn re: paper by
Milanowski et al. (Respir Med 1999; 93:
245±251)We would like to thank Dr Lipworth and Prof. Chrystyn
for their interest and comments, which point to a number of
important issues in the design of inhaled corticosteroid
trials and their application to asthma treatment. They are
quite correct in pointing to the diculty of demonstrating
relative potency of inhaled corticosteroids at high doses and
the importance of assessing equivalence also at low doses.Indeed, the focus of the high dose study (2000mg day71)
was primarily on demonstrating comparable safety and
tolerability of BDP-HFA and BDP-CFC, while the lower
dose study was designed to evaluate ecacy and safety in
patients not currently maintained on inhaled steroids. This
showed significant and equivalent improvement in lung
function and asthma symptoms with both treatments,
Moreover, the lung function responses seen in the
Milanowski et al., studies are in keeping with responses
seen in other published studies of high dose inhaled
corticosteroids (1,2). We would dispute the point by
Chrystyn concerning the studies being under-powered to
provide evidence of equivalence since both were planned
with full statistical considerations in determining detection
of any clinically relevant dierences between the hydro-
fluoroalkane (HFA) and chlorofluorocarbon (CFC) pro-
ducts.
The issue of assessing ecacy at low doses has in fact
already been addressed in another 12 week study in 200
asthmatic children with a beclomethasone dipropionate
(BDP) dose of 100 mg b.d., using similar formulations of
CFC and CFC-free BDP to those used in the adult
asthmatic study by Milanowski et al., 1999. This paediatric
study has also shown significant mean improvements in
PEF for both BDP-CFC and BDP-HFA that were within
3% of each other at endpoint (95% Cl 991, 1062%), with
similar equivalence in other ecacy and tolerability
parameters. It is intended that these data be published in
due course.
Thus therapeutic equivalence of these BDP-HFA and
BDP-CFC formulations (Norton Healthcare Ltd, U.K.)
has now been demonstrated across a wide dose range in
patients with all severities of asthma.
The pharmacokinetic data of Lipworth and Jackson and
the hypothetical lung deposition referred to by Chrystyn,
although interesting, are not necessarily reflected in clinical
practice in terms of asthma control. Caution must be
exercised when interpreting systemic steroid absorption
from both swallowed and inhaled drug. It is not stated
whether their data were acquired from healthy volunteers
or patients with asthma, but it is likely that the ratios of
plasma beclomethasone-17 monopropionate from inhaled
BDP-CFC and BDP-HFA will vary between subjects and
also across doses, as well as with inhaler technique. Taking
an arbitrary mean dose ratio from pharmacokinetic data
based on systemic absorption and then switching patients
to a lower inhaled dose of BDP-HFA when changing from
BDP-CFC exposes some patients to a risk of under-
treatment and possible asthma exacerbation. Based on the
evidence from our own studies, where the aim was to
evaluate therapeutic equivalence, it is not only justified, but
would appear far simpler and less risky, as well as being
more convenient for asthma suerers and health profes-
sionals, to switch patients on a 1:1 basis when changing
from BDP-CFC to BDP-HFA. Doses can later be titrated
down on an individual basis in a manner consistent with
good current practice (e.g. BTS guidelines). As to the
potential for the HFA product to result in a less favourable
safety profile, this has not been the case with BDP-HFA in
these studies nor in the post-marketing experience with this
